The original success of Sildenafil undeniably transformed the pharmaceutical landscape, but betting in companies strongly reliant on generic versions presents a uncertain picture. Despite early earnings were impressive, the end of patents and the appearance of less expensive alternatives have diminished sales. Consequently, a thorough assessment of